{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:10:02Z","timestamp":1791216602991,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the diagnostic value of serum neurofilament light chain (NFL) for discriminating Parkinson disease (PD) from Essential tremor (ET) and healthy controls, and to evaluate its correlation with some clinical features of PD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study measured NFL levels with electrochemiluminescence immunoassay in serum of 146 PD patients, 82 ET patients and 60 age-matched healthy controls. We used multivariate regression analyses to examine whether NFL contributes to PD biomarkers. Disease severity were assessed by Unified Parkinson\u2019s Disease Rating Scale part III (UPDRS III), Hoehn &amp; Yahr (H-Y) stage and Mini-Mental State Examination (MMSE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum NFL levels were significantly higher in PD than in ET and healthy controls (16.6\u2009\u00b1\u20093.5, 12.2\u2009\u00b1\u20092.4 and 11.8\u2009\u00b1\u20092.4\u2009pg\/mL, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In patients with PD, serum NFL were markedly increased in patients with advanced H-Y stage and patients with dementia (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The correlation analysis revealed that serum NFL was positively associated with UPDRS III score (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.79,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and H-Y stage (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and negatively correlated with MMSE scores (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Further multivariate regression analyses showed that serum NFL was an independent contributor to motor symptom and cognition severity in PD patients (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum NFL levels were markedly elevated may be a useful clinical biomarker for discriminating PD patients from ET and controls. Serum NFL may serve as a potential blood biomarker for motor and cognition severity of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02558-9","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T07:03:10Z","timestamp":1643266990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity"],"prefix":"10.1186","volume":"22","author":[{"given":"Yixian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"2558_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912.","journal-title":"Lancet"},{"key":"2558_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837\u201344.","journal-title":"Mov Disord"},{"key":"2558_CR3","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00702-012-0878-8","volume":"119","author":"U Bonuccelli","year":"2012","unstructured":"Bonuccelli U. Essential tremor is a neurodegenerative disease. J Neural Transm (Vienna). 2012;119:1383\u20137.","journal-title":"J Neural Transm (Vienna)"},{"issue":"Suppl 1","key":"2558_CR4","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.parkreldis.2017.07.006","volume":"46","author":"M Algarni","year":"2018","unstructured":"Algarni M, Fasano A. The overlap between essential tremor and Parkinson disease. Parkinsonism Relat Disord. 2018;46(Suppl 1):S101\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"2558_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247\u201357.","journal-title":"Neurology"},{"key":"2558_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","volume":"24","author":"F Piehl","year":"2018","unstructured":"Piehl F, Kockum I, Khademi M, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2018;24:1046\u201354.","journal-title":"Mult Scler"},{"key":"2558_CR7","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius \u00c5, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90:e518\u201324.","journal-title":"Neurology"},{"issue":"6","key":"2558_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(20)30137-X","volume":"19","author":"YT Quiroz","year":"2020","unstructured":"Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 2020;19(6):513\u201321.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2558_CR9","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH, Li CH, Yang KC, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93(11):e1104\u201311.","journal-title":"Neurology"},{"issue":"13","key":"2558_CR10","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92(13):e1479\u201386.","journal-title":"Neurology"},{"issue":"2","key":"2558_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","volume":"35","author":"LP Oosterveld","year":"2020","unstructured":"Oosterveld LP, Verberk IMW, Majbour NK, et al. CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson's from controls. Mov Disord. 2020;35(2):288\u201395.","journal-title":"Mov Disord"},{"issue":"6","key":"2558_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019;18(6):573\u201386.","journal-title":"Lancet Neurol"},{"key":"2558_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 3","key":"2558_CR14","first-page":"2","volume":"13","author":"G Deuschl","year":"1998","unstructured":"Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on tremor. Ad Hoc Scientific Committee Mov Disord. 1998;13(Suppl 3):2\u201323.","journal-title":"Ad Hoc Scientific Committee Mov Disord"},{"key":"2558_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427\u201342.","journal-title":"Neurology"},{"key":"2558_CR16","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease, vol 2","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R. Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden CD, Caine DB, Goldstein M, editors. Recent developments in Parkinson\u2019s disease, vol 2. Florham Park: Macmillan Health Care information; 1987. p. 153\u201363. 293\u2013304."},{"key":"2558_CR17","unstructured":"Fahn, S.; Tolosa, E.; Marin, C. Clinical Rating Scale for Tremor. In Parkinson\u2019s Disease and Movement Disorders;Jankovic, J., Tolosa, E., Eds.; Urban & Schwarzenberg: Baltimore-M\u00fcnich, WA, USA, 1988; pp. 225\u2013234."},{"key":"2558_CR18","first-page":"1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. Parkinson Study Group Neurol. 1990;40:1529\u20132134.","journal-title":"Parkinson Study Group Neurol"},{"key":"2558_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013837.","journal-title":"Mov Disord"},{"key":"2558_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society task force guidelines. Mov Disord. 2012;27:349\u201356.","journal-title":"Mov Disord"},{"key":"2558_CR21","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops S, Nazem S, Siderowf AD, Duda SX, Stern MB, Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73:1738\u201345.","journal-title":"Neurology"},{"key":"2558_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179\u201386.","journal-title":"Gerontologist"},{"issue":"10","key":"2558_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2558_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2558_CR25","doi-asserted-by":"publisher","unstructured":"Lerche S, Wurster I, R\u00f6ben B, et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov Disord. 2020. https:\/\/doi.org\/10.1002\/mds.28056, https:\/\/doi.org\/10.1002\/mds.28056.","DOI":"10.1002\/mds.28056 10.1002\/mds.28056"},{"issue":"4","key":"2558_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","volume":"72","author":"SY Wang","year":"2019","unstructured":"Wang SY, Chen W, Xu W, et al. Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and Meta-analysis. J Alzheimers Dis. 2019;72(4):1353\u201361.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2558_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neulet.2012.04.054","volume":"518","author":"ED Louis","year":"2012","unstructured":"Louis ED, Ma K, Babij R, et al. Neurofilament protein levels: quantitative analysis in essential tremor cerebellar cortex. Neurosci Lett. 2012;518(1):49\u201354.","journal-title":"Neurosci Lett"},{"key":"2558_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2019.00254","volume":"11","author":"M Jin","year":"2019","unstructured":"Jin M, Cao L, Dai YP. Role of Neurofilament light chain as a potential biomarker for Alzheimer's disease: a correlative Meta-analysis. Front Aging Neurosci. 2019;11:254.","journal-title":"Front Aging Neurosci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T07:03:16Z","timestamp":1643266996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2558"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02558-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Human Ethics Committees of the Second Affiliated Hospital of Soochow University. Informed consent was obtained for experimentation with human subjects. Every individual was informed about the aims of the study and provided written consent before participation. Written Informed consent was obtained from healthy controls and from the legal guardian\/next of kin for Parkinson\u2019s Disease patients. All methods were carried out in accordance with relevant guidelines and regulations\/Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}